{"id":3519,"date":"2021-01-28T19:39:26","date_gmt":"2021-01-29T03:39:26","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3519"},"modified":"2021-01-29T19:40:35","modified_gmt":"2021-01-30T03:40:35","slug":"efficacy-of-colchicine-in-non-hospitalized-patients-with-covid-19","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/28\/efficacy-of-colchicine-in-non-hospitalized-patients-with-covid-19\/","title":{"rendered":"Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19"},"content":{"rendered":"

[Pre-print, not peer-reviewed]<\/i> In a randomized, double-blinded, placebo-controlled trial (n=4,159), the anti-inflammatory medication colchicine reduced the rate of COVID-19-associated hospitalization or death among high-risk participants with COVID-19 who were not yet hospitalized. Participants who received colchicine for 30 days experienced 25% lower odds of hospitalization (95% CI 0.57-0.99), but not statistically significant lower odds for mechanical ventilation (OR=0.5, 95% CI 0.23-1.07), and death (OR=0.56, 95% CI 0.19-1.66) compared to those who received placebo. Serious adverse events were less frequent in the colchicine group (4.9% vs 6.3%), though diarrhea was more likely (13.7% vs 7.3%).<\/p>\n

Tardif et al. (Jan 27, 2021). Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Pre-print downloaded Jan 28 from <\/i>https:\/\/doi.org\/10.1101\/2021.01.26.21250494<\/a>\u00a0<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"

[Pre-print, not peer-reviewed] In a randomized, double-blinded, placebo-controlled trial (n=4,159), the anti-inflammatory medication colchicine reduced the rate of COVID-19-associated hospitalization or death among high-risk participants with COVID-19 who were not yet hospitalized. Participants who received colchicine for 30 days experienced 25% lower odds of hospitalization (95% CI 0.57-0.99), but not statistically significant lower odds for…<\/p>\n

Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-3519","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3519"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3519\/revisions"}],"predecessor-version":[{"id":3520,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3519\/revisions\/3520"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3519"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}